Abstract
Objective To investigate the efficacy and adverse reaction of erlotinib in 2nd and 3rd treatment of advanced non-small cell lung cancer (NSCLC) patients with failed prior chemotherapy.Methods Patients with advanced NSCLC(ⅢB/IV stage),who failed to prior chemotherapy,were recruited in this study,from March 2008 to June 2010.Erlotinib was given orally to the patients at 150 mg/d,once daily until disease progression.The clinical outcome and adverse reaction were observed.Patients were followed up.Kaplan-Meier method was used to perform survival analysis.Results Forty-five NSCLC patients were enrolled into the study and followed up until September 30,2010.42%patients with complete response and partial response.Disease control rate was 77.8%.Median time to progression and median overall survival period were 8 and 15 months,respectively.The main adverse reactions are I to Ⅱ grade skin rashes and diarrhea.Conclusions Erlotinib is an effective agent in treatment of advanced NSCLC patients after failure of chemotherapy.It is also effective in treating the patients of our country with unkown EGFR mutation status,and the tolerance is well. Key words: Erlotinib; Advanced non-small cell lung cancer
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
